Human Data Can’t Wait for Clinical Trials.
3D HUMAN BIOLOGY-ON-A-CHIP FOR HUMANIZED DRUG DISCOVERY AND CLINICAL DECISION MAKING
Accelerating drug discovery with AIM Biotech’s humanized BioAvatar products & services.
From the most demanding basic research, to predictive screens for drug discovery, to the tailored selection of precision medicines, AIM Biotech enables and accelerates the development of cutting-edge therapeutics. This is made possible through AIM Biotech’s BioAvatar technology, which embodies our core expertise in the design and manufacture of sophisticated microfluidic systems and human tissue models. Our BioAvatars combine unmatched recapitulation of human biology with unparalleled ease-of-use, resulting in a powerful solution to move medicine forward.
BioAvatars enable:
Humanized pre-clinical insights for increased predictability of clinical outcomes
Acceleration of the drug discovery process through easy-to-implement humanized organ-on-a-chip models
Replacement of animal models in pre-clinical trials
Explore AIM Biotech Solutions for Humanized Drug Discovery and Functional Precision Medicine
Introducing organiX: specifically made for Organoids and Biopsies
organiX is a revolution in Human Tissue and Biopsy Culture for Functional Precision Medicine and Drug Discovery
Designed to enable drug discovery and targeted therapies in large tissue samples like biopsies, organoids, tumoroids, spheroids and tissue aggregates, organiX allows for the detailed recreation of tissue and tumor microenvironments that is missing from current organoid research.
The ability to create actual physiological context for the study of these larger tissue samples is what sets organiX apart.
organiX Plate - Human Tissue | Translated.
Amplify the power of organoid research and biopsy characterization with organiX
Culture – biopsies, organoids, tumor tumoroids, spheroids or any cell/tissue aggregate up to 2 mm in diameter
Contextualize – set assay conditions with perfusable vasculature, co-culture, signaling gradients and media flow for an in vivo-like tumor microenvironment (TME)
Extract – First, obtain real time high resolution imaging data and then easily extract tissue samples for downstream analysis
Level Up! – Now revolutionize your fully contextualized organoid research utilizing conventional immunohistochemistry and next generation technologies like Digital Spatial Profiling
Your study. Our lab. Human data.
Contract research services for humanized, organ-on-a-chip studies
With AIM Biotech contract research services, increasing throughput while maintaining assay sophistication is our expertise. Our pharma-focused solutions combine speed and simplicity with the ability to model complex tissues that you expect from organ-on-a-chip assays.
Let AIM Biotech accelerate your drug discovery programs using our humanized BioAvatar Technology in our state-of-the-art research services lab. Our team can even work with you to design, develop, and execute custom assays to deliver human-focused, clinically-relevant results that move your drug discovery programs forward.
Custom assay development
Rapid humanized throughput
Functional immuno-oncology assays
Answer primary research questions
Data on routine screens
In-vitro organ models
Your path to predictive data and insightful diagnostics.
Products
Simple-to-use, fully scalable microfluidic systems in plate and chip formats to recapitulate human physiology.
Assays
Validated protocols in T-cell efficiency, immunotherapies, cell migration, vasculogenesis and more
Services
Custom assay development and higher-throughput, high-content screening with assays of your choice
Research
Feasibility studies
Drug/target ID
Mechanism of action
Assay development
Drug Discovery
In vitro screening
Lead optimization
ADME toxicity studies
Safety pharmacology
Diagnostics
Biomarkers
Cohort selection
Personal/targeted Tx
Clinical avatar
European Parliament votes to end animal testing in favor of using human models
In a major win for both animal rights and organ-on-a-chip technology, the EU has voted in favor of transitioning away from animal testing. Check out this article from Humane Society International.
Drug discovery evolves: Jump-starting the transition from animal models to human preclinical models
The limitations of animal and in vitro studies are beginning to change with the advent of organ-on-a-chip technologies. Check out this article about AIM Biotech on drugdiscoverytrends.com.
The AIM Biotech product family is getting multiplied
AIM’s 3D cell culture technology has always been about empowering preclinical research with better data and more predictive, humanized models. Powered by technology developed in the research labs of Dr. Roger Kamm at the Massachusetts Institute of Technology, the flexibility of our models to...